Introduction
============

Cisplatin (DDP) and 5-FU-based chemotherapy regimens constitute an important component of multimodal cancer treatment, but acquisition of resistance to these standard chemotherapeutic agents is a major challenge in the management of cancer [@B1], [@B2], including esophageal cancer which is the sixth most common cause of death worldwide with a 5-year survival rate of \~14% [@B3]. Therefore, comprehensive elucidation of the mechanisms governing chemoresistance and development of strategies to overcome chemoresistance are urgently needed.

MicroRNAs (miRNAs) are non-coding small RNAs of 19-22 nucleotides that negatively modulate protein expression [@B4], [@B5]. Their potential as diagnostic and prognostic biomarkers in cancer and other diseases has been documented [@B6]-[@B10]. Increasing evidence shows that miRNAs significantly contribute to different malignant phenotypes including chemoresistance [@B11]-[@B18]. However, there are few studies that identify and experimentally validate chemoresistance-related miRNAs in esophageal squamous cell carcinoma (ESCC). In our previous study, we established ESCC cell line models of acquired chemoresistance to fluorouracil (5-FU) (FR cells) [@B19]. By profiling the miRNA expression between parental cells and resistant cells in the present study, miR-29c-3p (referred to as miR-29c) was found to be one of the differentially expressed miRNAs in the FR cells, suggesting its potential role in modulating chemoresistance. However, the role of miR-29c in 5-FU chemoresistance has not been reported previously.

Here, we identified F-box only protein 31 (FBXO31), a novel F Box protein with prognostic significance in ESCC [@B20], as a protein that was upregulated in FR cells and a potential target of miR-29c. Our previous studies demonstrated that FBXO31 deactivates MAPK p38 and JNK signaling in ESCC cells subjected to genotoxic stresses, and that this mechanism contributes to DDP chemoresistance [@B20], [@B21], but the functional role of FBXO31 in 5-FU chemoresistance and its regulatory mechanisms have not been reported. In this study, the potential of miR-29c as a non-invasive biomarker and its mechanism in 5-FU chemoresistance of ESCC were investigated. Moreover, the efficacy of systemic delivery of miR-29c as cancer therapeutics was evaluated.

Methods
=======

Cell culture and drugs
----------------------

The 5-FU-resistant human ESCC sublines KYSE150FR and KYSE410FR, established through continuous treatment of KYSE150 and KYSE410 (DSMZ, Braunschweig, Germany) [@B22] with increasing concentrations of 5-FU [@B19], were maintained in RPMI 1640 (Sigma, St. Louis, MO,USA) supplemented with 10% fetal bovine serum (Invitrogen, Gaithersburg, MD, USA) at 37ºC in 5% CO~2~. Fluorouracil was purchased from Calbiochem (Darmstadt, Germany) and dissolved in dimethyl sulfoxide (DMSO). Cisplatin was purchased from Merck (Kenilworth, NJ, USA).

ESCC tumor, serum samples and tissue microarray
-----------------------------------------------

All clinical samples were collected with informed consent following approval by the Queen Mary Hospital (Hong Kong), Zhengzhou University (Zhengzhou, China) and Shantou University (Shantou, China). Primary tumors and the corresponding adjacent non-tumorous esophageal tissues were collected from a cohort of 50 patients who received frontline surgery without any prior chemoradiotherapy between 2011 and 2012 at the Queen Mary Hospital, and at the First Affiliated Hospital, Zhengzhou University from 2008 to 2010. Another independent cohort of 32 patients with survival data who underwent surgical resection without pre- operative chemoradiotherapy at Queen Mary Hospital was also included in this study. All tissues were frozen immediately in liquid nitrogen for subsequent protein or RNA extraction. In addition, serum samples from 50 healthy controls and 114 preoperative serum samples from patients who subsequently received 5-FU- and DDP-based neoadjuvant chemoradiotherapy were obtained from Shantou University Medical College and Queen Mary Hospital respectively. A tissue microarray containing 104 cases of ESCC and 75 cases of non-tumor tissue (Shanghai Outdo Biotech, Shanghai, China) was used to determine expression of STAT5A.

Taqman miRNA profiling
----------------------

Total RNA from cells was extracted using Trizol reagent according to the manufacturer\'s protocol (Invitrogen), and the quality of total RNA was assessed with the Agilent 2100 Bioanalyzer Platform (Agilent Technologies, Santa Clara, CA, USA). Reverse transcription was performed with Megaplex RT primers (Applied Biosystems, Carlsbad, CA, USA), and the miRNA expression profiles were determined with TaqMan human MicroRNA Low- Density Array Set (Applied Biosystems). Expression levels were normalized against endogenous U6 small nuclear RNA.

Plasmids, transfection and infection
------------------------------------

The transient expressing plasmids of miR-29c (pcDNA6.2-GW/EmGFP-miR-29c) and the scrambled miRNA control (pcDNA6.2-GW/EmGFP-miR-CON) were constructed using the Block-iT Pol II miR RNAi Expression Vector kit (Invitrogen). The pLenti- CMV-miR-29c and pLenti-CMV-miR-CON constructs used for stable expression were established using the Gateway approach (Invitrogen). The plasmids expressing miR-zip-29c and miR-zip-CON were purchased from System Biosciences (Palo Alto, CA, USA). The miR-29c mimic, miR-29c inhibitor and the negative controls were purchased from Ambion Inc (Austin, TX, USA). The FBXO31-overexpressing and -knockdown plasmids were prepared as described in our previous paper [@B21]. The 3\'UTR of FBXO31 was introduced into pGL3-control to establish the pGL3-FBXO31-3\'UTR plasmid. The pGL3-basic plasmid containing the promoter of miR-29c, pGL3- miR29c-pro-WT, was kindly provided by Professor Carlos Lo´pez-Otı´n (Universidad de Oviedo, Spain). Full-length STAT5A was obtained by PCR amplification and cloned into the pcDNA3 vector (Invitrogen). The siRNAs against STAT5A (si-STAT5A) were purchased from TranSheep Bio (Shanghai, China) and the target sequences were 5\'-gcaacctgtggaacctgaaaccatt-3\' for si-STAT5A\#1 and 5\'-atggatatgtgaaaccaca-3\' for si-STAT5A\#2. The STAT5A-knockdown plasmids were purchased from TranSheep Bio. Transfection was peformed using Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer\'s instructions. For infection, 293T cells were transfected with lentiviral plasmids and packaging mix (Invitrogen) using Lipofectamine 2000, and the virus-containing culture media were collected and used to infect target cells, and the stable cell lines were selected with puromycin. The cells with stable overexpression of miR-29c were established and maintained at least two weeks before experiments.

Reverse transcription and quantitative real time polymerase chain reaction (qRT-PCR)
------------------------------------------------------------------------------------

Total RNA was extracted using Trizol reagent (Invitrogen) according to the manufacturer\'s protocol as previously described [@B23]. MicroRNA was converted to cDNA using the miScript II RT Kit (Qiagen, Hilden, Germany), and qPCR was performed using the miScript SYBR® Green PCR Kit (Qiagen). The forward primers for the 12 shortlisted miRNAs are listed in Table [S1](#SM0){ref-type="supplementary-material"}. Taqman MicroRNA Reverse Transcription kit and Taqman miRNA assays (Applied Biosystems) were also used to determine the expression of miR-29c and that of U6 as control [@B23]. All the experiments were performed on MyIQTM2 Real-Time PCR Detection System (Bio-Rad, Hercules, CA, USA). The expression level of miR-29c was categorized into "high" and "low" using the median value as cut-off point.

Chromatin immunoprecipitation-quantitative PCR (ChIP)
-----------------------------------------------------

The chromatin immunoprecipitation (ChIP) assay was performed by using simple ChIP enzymatic chromatin IP kit (Cell Signaling, Beverly, MA, USA) according to the manufacturer\'s manual as described previously [@B23]. In brief, *in vivo* protein and DNA crosslinking was performed using 37% formaldehyde, followed by sonication and chromatin digestion. The protein-DNA complexes were immunoprecipitated using STAT5A antibody or negative control IgG antibody. The purified DNA was subjected to SYBR Green PCR analysis (Bio-Rad). Relative mRNA expression was calculated using the comparative Ct method after normalization to GAPDH control.

Western blot
------------

Western blot was performed as previously described [@B24]. The primary antibodies used included FBXO31 antibody from Abcam (Cambridge, UK), caspase-3 and cleaved caspase-3 from Cell Signaling Technology, phosphorylated p38 (p-p38), p38 from BD Biosciences (San Diego, CA, USA), STAT5A from Proteintech (Rosemont, IL, USA) and actin from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

MTT assay
---------

Cell viability was determined as described previously [@B25]. Briefly, cells were plated in 96-well plates at a density of 1000 cells per well, and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was added at the end of experiment. The absorbance was measured at a wavelength of 570 nm on an automated microplate spectrophotometer (BioTek Instruments, Winooski, VT, USA).

Colony formation assay
----------------------

Cells were seeded onto 6-well plates at a density of 500 cells per well and cultured for 14 days, and then fixed in 75% ethanol and stained with 0.2% crystal violet. The number of colonies was counted [@B26].

Flow cytometry analysis
-----------------------

Apoptosis was evaluated using an annexin V‐fluoroisothiocyanate apoptosis detection kit according to the manufacturer\'s instructions (KeyGen Biotech, Jiangsu, China). In brief, cells were pelleted by centrifugation and then resuspended in 100 μL of annexin V binding buffer. After incubation, cells were washed and subjected to flow cytometer analysis. The data were analyzed by FlowJo software (FlowJo LLC, Ashland, OR, USA).

Site-directed mutagenesis and luciferase assay
----------------------------------------------

QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent Technologies) was used to generate constructs that expressed mutated 3\'UTR of FBXO31 and mutation of pGL3-miR29c-pro-WT. The primers used are listed in Table [S2](#SM0){ref-type="supplementary-material"}. The luciferase activity was measured by using dual-luciferase reporter assay (Promega, Madison, WI, USA) as previously described [@B19].

Tumor xenograft experiment
--------------------------

All the animal experiments were approved by the Committee on the Use of Live Animals in Teaching and Research, the University of Hong Kong, or Jinan University. Female BALB/c nude mice aged 6-8 weeks were used. Tumor xenografts were established as described previously [@B27]. When the subcutaneous tumors reached \~5 mm diameter, the mice were intraperitoneally injected twice weekly with 5-FU (20 mg/kg) or vehicle. In the experiment involving systemic miR-29c treatment, KYSE410FR cells were subcutaneously injected into mice and the mice were randomized into four groups when the tumors reached \~5 mm in diameter. The miR-29c oligonucleotide or miR-CON (GenePharma, Shanghai, China) was formulated with a polymer-based agent (*in vivo*-jetPEI^TM^; Polyplus, Illkirch, France) as described previously [@B28] and injected intravenously into mice with or without 5-FU treatment. Tumor size was monitored with caliper every three days, and tumor volume was calculated using the equation V= (length x width^2^)/2. All measured tumor sizes were normalized to the average tumor volume of the corresponding DMSO-treated group. Tumors were collected for immunohistochemistry and Western blot analyses.

Immunohistochemistry
--------------------

Immunohistochemistry analysis was performed on the paraffin-embedded tumor sections as previously described [@B29]. After antigen retrieval and blocking with normal serum, the slides were incubated with Ki-67 antibody (Dako, Mississauga, ON, Canada) or STAT5A antibody (Proteintech) overnight at 4 ºC, washed with phosphate buffered saline, followed by biotinylated secondary antibody and peroxidase-conjugated avidin-biotin complex (Dako). Immunostaining was visualized using 3,3\'-diaminobenzidine (Dako), which served as a chromogen, and the sections were counterstained with hematoxylin. Ki-67 proliferation index and staining scores for STAT5A were determined as described previously [@B25], [@B30]. For STAT5A, specimens assigned scores of 0\~1 were categorized as low expression, whereas scores 2\~3 were determined as high expression.

Hematologic analyses
--------------------

Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in mouse serum were determined using commercial kits (HuiLi Biotech Ltd., Changchun, China). Hemoglobin (HGB) and blood cells from mice including lymphocytes, neutrophils, platelets (PLT), red blood cells (RBC) and white blood cells (WBC) were analyzed by a fully automatic hematology analyzer (BC-2800Vet, Mondrary, Shenzhen, China).

Bioinformatics study
--------------------

Two transcription factor binding site prediction software programs ConTra V2 [@B31] and TRRD [@B32] were used to identify the potential STAT5A binding sites in the promoter region of miR-29c (chr1 207995872-208000037). Two software programs including TargetScan (<http://www.targetscan.org/vert_> 50/) and miRanda (<http://www.microrna.org/microrna/getExpr> Form.do) were used to predict the biological targets of miR-29c, as previously described [@B23].

Public datasets analysis
------------------------

The expression values of miR-29c and clinical data were retrieved from the public datasets and analyzed as previously described [@B29]. The expression values of miR-29c in different cancer types in TCGA datasets were analyzed via OncomiR website (http:// [www.oncomir.org/oncomir/search_miR_tumor.html](http://www.oncomir.org/oncomir/search_miR_tumor.html)). The values were divided as low and high using the 50% value as cut-off point.

Statistical analysis
--------------------

The data were expressed as the mean ± SD and compared using ANOVA. The association between the expression levels of miR-29c and FBXO31 was determined using Pearson rank correlation coefficient. The expression level of miR-29c in tumor and serum samples was compared with that in non-tumor tissues and healthy control serum, respectively, using paired or unpaired t-test. The correlation between miR-29c and clinicopathological parameters was assessed using Fisher exact test. Survival analysis was performed by Kaplan-Meier method with the log-rank test. *P* values \< 0.05 were deemed significant. All *in vitro* experiments were repeated at least three times.

Results
=======

miR-29c is downregulated in 5-FU chemoresistant ESCC cells
----------------------------------------------------------

In order to screen and identify the miRNAs which regulate 5-FU chemoresistance, a miRNA microarray was used to profile the miRNAs differentially expressed between FR cells (KYSE150-FR) and parental KYSE150 cells. A literature search was conducted for the top 100 downregulated miRNAs (Table [S3](#SM0){ref-type="supplementary-material"}) to narrow the candidates. Sixty-seven miRNAs were discarded because they are frequently upregulated in a wide variety of cancer and therefore less likely to have tumor-suppressive function in ESCC (Figure [S1](#SM0){ref-type="supplementary-material"}A). Of the remaining 33 miRNAs, we further excluded 21 miRNAs which had already been reported to be related to chemoresistance, leaving 12 novel ones for further validation (Table [S1](#SM0){ref-type="supplementary-material"}). Our qRT-PCR data showed that, among the 12 shortlisted candidates, miR-29c was the most consistently and significantly decreased miRNA in two FR sublines, compared with corresponding parental cells (Figure [S1](#SM0){ref-type="supplementary-material"}B-C), suggesting its potential role in regulating chemoresistance.

miR-29c is aberrantly downregulated and correlated with poor survival outcome in patients with several types of cancer
----------------------------------------------------------------------------------------------------------------------

To investigate the clinical significance of miR-29c in ESCC, the expression of miR-29c was determined in a cohort including 32 pairs of tumors and matched adjacent non-tumor tissues by qRT-PCR. The results showed that miR-29c expression was significantly lower in tumor tissues than adjacent non-tumor tissues (*P* \< 0.001) (Figure [1](#F1){ref-type="fig"}A), and that downregulation was detected in 90.6% (29/32) of ESCC cases (Figure [1](#F1){ref-type="fig"}B). As shown in Figure [1](#F1){ref-type="fig"}A, the mean miR-29c expression in the tumor tissues was about 3.9-fold lower than that in the paired non-tumor tissues. More importantly, our results showed that miR-29c was significantly associated with overall survival of ESCC patients, with the mean survival time dropping from 36.8 months in the patients with high miR-29c expression to 17.0 months in the patients with low miR-29c expression (Figure [1](#F1){ref-type="fig"}C). Taken together, these data suggest that miR- 29c could be a prognostic marker to predict the outcome of ESCC patients. By analyzing the Gene Omnibus Express (GEO) and TCGA datasets, we found frequent downregulation of miR-29c in tumor tissues of multiple cancer types, compared with non- tumor tissues (Figures S2A and S3A). In the public databases, low miR-29c expression was also associated with poor prognosis in several other cancer types (Figures S2B and S3B).

High expression level of miR-29c in serum is associated with better prognosis in patients with ESCC
---------------------------------------------------------------------------------------------------

We further explored the clinical relevance of miR-29c as a non-invasive marker in ESCC by comparing the expression level of miR-29c in admission serum samples of 114 ESCC patients with that in serum samples of 50 healthy individuals. The expression level of serum miR-29c was significantly downregulated in the ESCC patients (Figure [1](#F1){ref-type="fig"}D). Moreover, Kaplan- Meier survival analysis showed that the ESCC patients with high serum miR-29c expression had significantly prolonged overall survival time (Figure [1](#F1){ref-type="fig"}E). Collectively, these data indicated that serum miR-29c level could predict the response of ESCC patients to chemoradiotherapy.

Ectopic expression of miR-29c overrides 5-FU chemoresistance in ESCC cells
--------------------------------------------------------------------------

To study the role of miR-29c in ESCC chemoresistance, miR-29c was stably overexpressed in two FR sublines (KYSE150FR-miR-29c and KYSE410FR- miR-29c) (Figure [S4](#SM0){ref-type="supplementary-material"}A), and then the cells were treated with 5-FU in functional assays. The results from MTT and colony-formation assays showed that ectopic expression of miR-29c overcame the resistance of KYSE150FR and KYSE410FR cells to 5-FU treatment (Figure [2](#F2){ref-type="fig"}A-B). Conversely, knockdown of miR-29c by miR-zip-29c (Figure [S4](#SM0){ref-type="supplementary-material"}A) markedly conferred 5-FU chemoresistance to ESCC cells (Figure [2](#F2){ref-type="fig"}C-D). Moreover, we found that miR-29c promoted apoptosis of the 5-FU-treated cells, indicated by the increased 5-FU-induced cleaved caspase-3 expression in miR-29c-overexpressing FR cells and the decreased 5-FU-induced cleaved caspase-3 expression in miR-29c-knockdown cells (Figure [2](#F2){ref-type="fig"}E-F). Flow cytometry confirmed the effects of miR-29c on apoptosis (Figure [S4](#SM0){ref-type="supplementary-material"}B). Taken together, these data demonstrated that miR-29c could enhance the sensitivity of ESCC cells to 5-FU.

In addition, we determined whether miR-29c dyregulation may contribute to DDP chemoresistance. ESCC cells with miR-29c-knockdown showed enhanced viability and colony formation ability, compared with the control cells expressing miR-zip-CON, when exposed to DDP, which suggests that miR-29c can sensitize ESCC cells to DDP treatment (Figure [S5](#SM0){ref-type="supplementary-material"}A-B).

FBXO31 is a direct target of miR-29c
------------------------------------

We next investigated the mechanism by which miR-29c regulates 5-FU resistance in ESCC cells. *In silico* analysis using TargetScan and MiRanda target prediction algorithms was performed to search for potential targets of miR-29c (Figure [3](#F3){ref-type="fig"}A). FBXO31, which we previously reported to have prognostic significance and regulatory function on DDP chemoresistance in ESCC [@B20], [@B21], was identified as a potential target of miR-29c. The binding site between miR-29c and FBXO31 3\'UTR is illustrated in Figure [3](#F3){ref-type="fig"}B. Interestingly, FBXO31 was found to be significantly upregulated in the FR cells, compared with the parental cells (Figure [3](#F3){ref-type="fig"}C). A decrease in FBXO31 expression and an increase in p-p38 expression were observed in the FR cell lines with stable overexpression of miR-29c (Figure [3](#F3){ref-type="fig"}D). Conversely, expression level of FBXO31 was upregulated, whereas p-p38 expression was downregulated, in the ESCC cells with stable knockdown of miR-29c (Figure [3](#F3){ref-type="fig"}E). The inhibitory effect of miR-29c on FBXO31 expression was confirmed by transient transfection of miR- 29c mimic or anti-miR-29c inhibitor (Figure [S6](#SM0){ref-type="supplementary-material"}A-B). To further study the significance of interaction between FBXO31 and miR-29c, dual-luciferase reporter assay was performed, plasmids expressing wild type FBXO31 3\'UTR and miR-29c, respectively, were co-transfected into KYSE150 cells, and the results showed that miR-29c overexpression led to a significant decrease in luciferase activity of FBXO31 3\'UTR in a dose-dependent manner (Figure [3](#F3){ref-type="fig"}F). However, the inhibitory effect of miR-29c on luciferase activity of FBXO31 3\'UTR was abolished when the binding site of miR-29c on FBXO31 3\'UTR was mutated (Figure [3](#F3){ref-type="fig"}G), confirming that miR-29c can directly bind to and decrease FBXO31 expression. Furthermore, the expression levels of miR-29c and FBXO31 were determined in 50 pairs of ESCC tumor and matched non-tumor tissues (Figure [S7](#SM0){ref-type="supplementary-material"}). Markedly higher expression of FBXO31 (Figures [3](#F3){ref-type="fig"}H) and lower expression of miR-29c (Figure [3](#F3){ref-type="fig"}I) were found in ESCC tissues compared with non-tumor esophageal tissues, and a significant inverse correlation between miR-29c and FBXO31 was observed (Figure [3](#F3){ref-type="fig"}J). These data make it evident that miR-29c affects FBXO31 expression by directly binding to its 3\'UTR region, thus suggesting that aberrant downregulation of miR-29c may enhance FBXO31-mediated chemoresistance in ESCC.

FBXO31 mediates the effect of miR-29c on 5-FU chemoresistance *in vitro* and *in vivo*
--------------------------------------------------------------------------------------

The effect of FBXO31 in 5-FU chemoresistance has not been reported previously. We found that knockdown of FBXO31 by stable transfection with shRNA FBXO31 (Figure [S8](#SM0){ref-type="supplementary-material"}A) significantly reduced 5-FU chemoresistance in KYSE150FR and KYSE410FR cells, as determined using MTT and colony formation assays (Figure [S8](#SM0){ref-type="supplementary-material"}B-C). To study whether FBXO31 mediates the effect of miR-29c on 5-FU chemoresistance, the endogenous FBXO31 expression in the FR ESCC cells was first suppressed by overexpressing miR-29c, which resulted in increased phosphorylation/activation of p38 (Figure [4](#F4){ref-type="fig"}A). Western blot analysis confirmed that these effects were abolished by co-expressing FBXO31 in the FR cells (Figure [4](#F4){ref-type="fig"}A). The FR cells co-overexpressing miR-29c and FBXO31 (KYSE150FR-miR-29c-FBXO31, KYSE410FR-miR-29c-FBXO31), or miR-29c alone (KYSE150FR-miR-29c-CON, KYSE410FR-miR-29c-CON), and the control cells (KYSE150-FR-miR-CON-CON, KYSE410FR-miR-CON-CON) were then treated with 10 μM 5-FU. The results from MTT assay showed that overexpression of miR-29c led to a significant increased sensitivity to 5-FU, and that this effect was significantly diminished when FBXO31 expression was restored (Figure [4](#F4){ref-type="fig"}B). Consistent results were obtained at a higher concentration of 5-FU (i.e. 20 μM) (Figure [S9](#SM0){ref-type="supplementary-material"}). Western blot data confirmed that miR-29c enhanced 5-FU-induced expression of cleaved caspase-3 in KYSE150FR and KYSE410 cells, whereas ectopic expression of FBXO31 significantly abrogated these effects (Figure [4](#F4){ref-type="fig"}C). On the contrary, inhibition of FBXO31 expression level with lentiviral shRNA in the miR-29c-knockdown ESCC cells (KYSE150-miR-zip- 29c-shFBXO31 and KYSE410-miR-zip-29c-shFBXO31) markedly counteracted the 5-FU chemoresistance induced by miR-29c knockdown, as indicated by Western blot and MTT assays (Figure [4](#F4){ref-type="fig"}D-F). We next performed flow cytometry and the results showed that FBXO31-knockdown significantly increased 5-FU-induced apoptosis (Figure [S10](#SM0){ref-type="supplementary-material"}).

We further performed *in vivo* experiment to validate these findings, and the results showed that ectopic miR-29c expression could override the resistance of FR tumor xenografts to 5-FU treatment in nude mice, and that overexpression of FBXO31 significantly attenuated this effect (Figure [4](#F4){ref-type="fig"}G-H). Collectively, these results demonstrated that miR-29c could sensitize ESCC cells to 5-FU treatment through downregulation of FBXO31 expression.

STAT5A regulates the expression of miR-29c at transcriptional level
-------------------------------------------------------------------

To obtain a better understanding of why miR-29c is underexpressed in ESCC,*in silico* prediction algorithm was applied to determine the upstream regulatory mechanism of miR-29c. Three potential binding sites for STAT5A were identified in the promoter region of miR-29c, suggesting that STAT5A may participate in the regulation of miR-29c. Gain- and loss-of-function experiments showed that STAT5A expression negatively regulated the expression of miR-29c (Figure [5](#F5){ref-type="fig"}A and Figure [S11](#SM0){ref-type="supplementary-material"}A). We also compared the expression of STAT5A in parental cells and corresponding FR cells, and noted that STAT5A did increase in the FR cells (Figure [S11](#SM0){ref-type="supplementary-material"}B). Chromatin immunoprecipitation-quantitative PCR (ChIP-qPCR) assay was carried out to investigate whether there is physical interaction between STAT5A protein and the promoter region of miR-29c. We found that, of the three potential STAT5A binding sites in the promoter region of miR-29c (designated as Site 1, Site 2 and Site 3), only the Site 3 fragment was enriched in the STAT5A immunoprecipitates (Figure [5](#F5){ref-type="fig"}B). Site-specific mutations and luciferase assay further confirmed that only Site 3, but not the other two fragments, functions as the STAT5A-responsive element (Figure [5](#F5){ref-type="fig"}C).

Western blot was undertaken to determine the effect of manipulation of STAT5A expression on FBXO31, and the results indicated a positive regulation as shown in Figure [S12](#SM0){ref-type="supplementary-material"}A. To study the significance of STAT5A in chemoresistance, shRNA against STAT5A was stably transfected into the KYSE150FR and KYSE410FR cells. The data from MTT assay and colony formation assays showed that knockdown of STAT5A significantly enhanced 5-FU sensitivity (Figure [S12](#SM0){ref-type="supplementary-material"}B-C).

The clinical relevance of STAT5A in ESCC is largely unknown. We made use of a tissue microarray consisting of 104 cases of primary ESCC tissues and 75 cases of non-tumor tissues and performed immunohistochemistry for STAT5A (Figure [5](#F5){ref-type="fig"}D). Fifty-one percent of the ESCC tumors received high immunohistochemical scores of 2 to 3, whereas 90.5% of non-tumor esophageal tissue samples showed no or weak staining (scores 0 to 1) (χ^2^ test, *P* \< 0.001) (Figure [5](#F5){ref-type="fig"}E-F). Survival analysis showed that STAT5A expression was negatively correlated with overall survival. Patients with low STAT5A expression had a longer survival (mean survival = 40.35 months) than the patients with high STAT5A expression (mean survival = 22.56 months) (Figure [5](#F5){ref-type="fig"}G). In addition, there is a significant inverse correlation between STAT5A expression and pathological N-stage (Table [1](#T1){ref-type="table"}). Furthermore, the expression of STAT5A was analyzed in the same 50 pairs of ESCC tumor and matched non-tumor tissues mentioned in Figure [3](#F3){ref-type="fig"}. The data showed a markedly higher expression of STAT5A in ESCC tissues compared with non-tumor esophageal tissues (Figure [S13](#SM0){ref-type="supplementary-material"}), and a significant inverse correlation between miR-29c and STAT5A (r = -0.287,*P* \< 0.01) (Figure [5](#F5){ref-type="fig"}H). Moreover, there was a positive correlation between STAT5A and FBXO31 (r = 0.495,*P* \< 0.001) (Figure [5](#F5){ref-type="fig"}I). We also selected 12 pairs of ESCC and matched non-tumor samples to determine the expression of p-p38, and found that p-p38 had an inverse correlation with FBXO31 and STAT5A (Figure [S14](#SM0){ref-type="supplementary-material"}A-C).

Systemic delivery of miR-29c increases chemosensitivity of ESCC cells to 5-FU *in vivo*
---------------------------------------------------------------------------------------

We next assessed the therapeutic potential of systemically delivered miR-29c in treating 5-FU chemoresistant ESCC. The 5-FU-resistant ESCC tumor xenografts were established by subcutaneously injecting KYSE410FR cells into the flanks of nude mice. We found that administration of a combination of miR-29c oligonucleotide and 5-FU resulted in a significant decrease in tumor volume compared with 5-FU treatment alone (Figure [6](#F6){ref-type="fig"}A-B). Furthermore, systemic miR-29c treatment facilitated 5-FU-induced apoptosis and suppressed proliferation of tumor cells, as indicated by increased expression of cleaved caspase-3 and p-p38 (Figure [6](#F6){ref-type="fig"}C) and decreased percentage of Ki-67-positive tumor cells (Figure [6](#F6){ref-type="fig"}D), respectively, in the tumor xenografts of mice treated with both 5-FU and miR-29c, compared with the groups treated with 5-FU or miR-29c alone. Notably, the administration of miR-29c did not cause toxicity to the mice, as evidenced by the lack of significant changes in body weight (Figure [6](#F6){ref-type="fig"}E), and blood biochemical and hematological parameters (Figure [6](#F6){ref-type="fig"}F).

Discussion
==========

Resistance to chemotherapy drugs is a major cause of tumor recurrence. A relapse phenotype may be due to pre-existing resistance of the original tumor to therapy (intrinsic resistance), or therapy-dependent selection of resistant cancer cells (acquired resistance) [@B2]. A number of miRNAs and their target genes are known to play a role in chemoresistance. The miR34a/GOLPH3 axis, for example, was reported to abrogate urothelial bladder cancer chemoresistance via reduced cancer stemness [@B18]. In another study, Lai *et al*. showed that miRNAs, namely miR-205-5p and miR-342-3p, can cooperate to repress E2F1 and thereby decrease tumor chemoresistance [@B33]. MiRNA arrays are frequently used to profile differentially expressed miRNAs in matched tumor tissues and adjacent non-tumor tissue [@B34], [@B35], but studies that make use of miRNA array to profile chemoresistance- related miRNAs are rare. This is the first study that used miRNA array to compare matched parental versus 5-FU chemoresistant cells to identify resistance-related miRNA signatures. The advantages of using matched parental versus resistant cells are obvious: 1) this cell model mimics the process of acquired chemoresistance, and this comparative approach allows us to capture the genetic alterations that occur during this process; 2) the use of matched cell lines with same genetic background can circumvent the confounding factor of massive genetic heterogeneity (associated with tumor tissues) which may create unnecessary interference in profiling resistance-related miRNAs. Using this approach, we have provided the first evidence of miR-29c downregulation in 5-FU resistant cancer cells, and shown that restoration of miR-29c can sensitize ESCC cells to 5-FU treatment *in vitro* and *in vivo* (Figures [2](#F2){ref-type="fig"} and [4](#F4){ref-type="fig"}).

Biomarkers that can facilitate early diagnosis and predict treatment response are instrumental in optimizing therapy and improving the outcome for patients with ESCC. The clinical significance of miR-29c dysregulation was evaluated in the present study (Figure [1](#F1){ref-type="fig"}). We found that the expression levels of miR-29c is significantly lower in primary ESCC tumor tissue compared with matched non-tumor tissues, and that high tumor miR-29c expression level predicts better survival. Our results also showed that serum miR-29c level has diagnostic significance, as reported previously by Xu *et al*, thus affirming its significance as a non-invasive marker for ESCC screening [@B36]. More importantly, the data from our larger cohort of patients demonstrate that serum miR-29c level has the potential to be a predictive marker for response to chemoradiotherapy.

The biogenesis of miRNAs is under tight control at various levels. A previous study showed that miR-29 is repressed by NF-kB through Yin Yang 1 (YY1) and the Polycomb group, and that disruption of this regulatory circuit contributes to rhabdomyosarcoma [@B37]. Another study demonstrated that miR-29 is under negative regulation by TGF-beta-Smad3 signaling via dual mechanisms of both inhibiting MyoD binding and enhancing YY1-recruited Polycomb association [@B38]. In our previous study, we showed that IGF2 regulates miR-29c at transcriptional level in a p53-dependent manner [@B23]. In this study, by using *in silico* prediction, followed by ChIP and gain- and loss-of-function study, we have uncovered another novel mechanism whereby STAT5A represses the transcription of miR-29c by directly binding to its promoter (Figure [5](#F5){ref-type="fig"}). The function of this mechanism in regulating FBXO31 expression and chemoresistance is represented schematically in Figure [7](#F7){ref-type="fig"}.

F-box proteins are well recognized as the substrate-recognition components of the SKP1/ CUL1/F-box protein (SCF) class of E3 ubiquitin ligases [@B39]. Our recent report showed that higher FBXO31 expression level is significantly correlated with histological grade, clinical stage and post-operative survival in patients with ESCC [@B20]. Another of our previous studies also showed that FBXO31 binds to MKK6 and decreases its protein stability, thereby negatively regulating the activation of p38 in cancer cells upon genotoxic stresses [@B21]. The molecular mechanism on upstream regulation of FBXO31 was unknown. Here, our results show for the first time that miR-29c directly binds to and represses the expression level of FBXO31. We further confirmed an inverse correlation between miR-29c and FBXO31 in 50 pairs of ESCC tissues (Figure [3](#F3){ref-type="fig"}). Our results showing that enforced expression of FBXO31 abolished the 5-FU-chemosensitizing effect of miR-29c in ESCC cells (Figure [4](#F4){ref-type="fig"}) revealed for the first time the key role of FBXO31 in mediating miR-29c-regulated 5-FU chemoresistance. Nevertheless, we do not rule out the possibility that other targets of miR-29c such as cyclin E may also mediate the chemosensitizing effects of miR-29c [@B40]. We have focused on FBXO31 in this study because its biological role of FBXO31 in cancer was rarely studied, and its potential function in 5-FU chemoresistance had not been reported.

In conclusion, this study establishes that miR-29c can sensitize ESCC cells to 5-FU treatment through regulation of FBXO31-p38 signaling, and that the expression levels of miR-29c in the tumor and serum of ESCC patients have diagnostic and prognostic significance. Our preclinical data, which proved that systemic delivery of miR-29c oligonucleotide could significantly alleviate the 5-FU chemoresistance of ESCC tumors, are strong evidence supporting the use of miR-29c as adjuvant therapy in the management of ESCC. Since a considerable percentage of ESCC overexpress STAT5A and STAT5A can suppress miR-29c, targeting STAT5A may be an additional strategy that is worth considering.
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ALT

:   Alanine aminotransferase

AST

:   aspartate aminotransferase

ChIP

:   Chromatin immunoprecipitation

DDP

:   cisplatin

DMSO

:   dimethyl sulfoxide

ESCC

:   esophageal squamous cell carcinoma

FBS

:   fetal bovine serum

FBXO31

:   F-box only protein 31

5-FU

:   fluorouracil

GEO

:   Gene Omnibus Express

HGB

:   Hemoglobin

miRNA

:   microRNA

MTT

:   3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide

PLT

:   platelets

RBC

:   red blood cells

SCF

:   SKP1/ CUL1/F-box protein

Taqman qRT-PCR

:   Taqman quantitative real time polymerase chain reaction

WBC

:   white blood cells.

![**Clinical significance of miR-29c in ESCC. (A)** Mean miR-29c expression in primary esophageal cancer (T) and the paired non-tumor tissues (N) was compared using Taqman qRT-PCR. The horizontal bars represent the mean values. **(B)** miR- 29c expression in 32 primary ESCC tumor samples relative to the corresponding non-tumor tissues. Lower expression of miR- 29c was observed in the majority of tumors examined (29/32, 90.6%), compared with their corresponding non-tumor tissues.**(C)** Kaplan-Meier analysis based on the 32 tumor tissues showing that miR-29c expression was positively associated with patient survival. **(D)** Serum miR-29c level in 114 cancer patients and 50 healthy control subjects. The horizontal bars represent mean values. **(E)** Kaplan-Meier analysis of overall survival of 114 patients with ESCC stratified according to admission serum miR-29c level.](thnov09p1599g001){#F1}

![**miR-29c expression sensitizes ESCC cells to 5-FU treatment. (A, B)** FR ESCC cells KYSE150FR and KYSE410FR which stably overexpressed miR-29c or the scrambled miRNA control were treated with 5-FU (10 μM) or DMSO for 48 hours, and then subjected to MTT assay **(A)** and colony formation assay **(B)**. **(C)** ESCC cells with miR-29c-knockdown and the control cells expressing miR-zip-CON were exposed to 5-FU (10 μM) for 48 hours, and cell viability was determined by MTT assay. **(D)** Colony formation assay showing the effect of miR-29c knockdown on the sensitivity of ESCC cells to 5-FU. **(E)** Expression levels of cleaved caspase-3 and caspase-3 were determined in the miR-29c-overexpressing cells and control cells upon 5-FU treatment by Western blot. Actin was included as loading control. **(F)** Western blot data showing that 5-FU could not induce expression of cleaved caspase-3 when miR-29c expression was inhibited in KYSE150 and KYSE410 cells. Bars, SD; \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001 compared with corresponding 5-FU treated control cells.](thnov09p1599g002){#F2}

![**FBXO31 is a target of miR-29c. (A)** Diagram showing the approach used to identify the putative targets of miR-29c by in silico software prediction. **(B)** Alignment of miR-29c and its corresponding complementary binding sequence in FBXO31 3\'UTR. **(C)** FBXO31 expression was determined in 5-FU-resistant ESCC cells and parental cells by Western blot. **(D)** Western blot analysis showing the effects of stable miR-29c overexpression on FBXO31, p-p38 and total p38 expressions in KYSE150FR and KYSE410FR cells. **(E)** Effects of stable knockdown of miR-29c on FBXO31, p-p38, p38 expressions in ESCC cells, as determined by Western blot. **(F)** Ectopic miR-29c expression caused dose-dependent decrease in the luciferase activity of FBXO31 3\'-UTR. **(G)** Luciferase activity in KYSE150 cells co-transfected with the indicated plasmids. Mutations introduced into the FBXO31 3\'UTR by site-directed mutagenesis to generate the mutant FBXO31 3\'UTR are shown above the graph. **(H)** Expression level of FBXO31 was determined in 50 pairs of ESCC (T) and matched non-tumor (N) tissues by Western blot. Graph showing the FBXO31 expression in the primary tumors which was quantified relative to that of corresponding non-tumor tissue samples. **(I)** Expression level of miR-29c was determined in the 50 pairs of ESCC tissues and non-tumor tissues by Taqman qRT-PCR. In the majority of the cases (46/50, 92.0%), miR-29c expression was lower in tumor tissues relative to the corresponding non-tumor tissues. **(J)** Inverse correlation between miR-29c and FBXO31 in clinical ESCC tissues. Bars, SD; n.s., no significance;\*\*, P \< 0.01.](thnov09p1599g003){#F3}

![**FBXO31 mediates the effect of miR-29c on 5-FU chemoresistance *in vitro* and *in vivo*. (A)** Western blot analyses showing that restoration of FBXO31 expression abolished p38 activation in miR-29c-overexpressing KYSE150FR and KYSE410FR cells. **(B, C)** KYSE150FR and KYSE410FR cells with stable overexpression of miR-29c, co-overexpression of miR-29c and FBXO31, or control plasmids, were treated with 5-FU (10 μM) or DMSO for 48 hours and then subjected to MTT assay **(B)** and Western blot analyses for detection of cleaved caspase-3 and caspase-3 **(C)**. **(D)** Western blots showing that knockdown of FBXO31 expression reactivated p38 in KYSE150 and KYSE410 cells with stable expression of miR-zip-29c. **(E,F)** Knockdown of FBXO31 abrogated the effect of miR-29c inhibition on enhancing the chemoresistance of ESCC cells to 5-FU treatment, as shown in MTT assay **(E)** and Western blot analysis of apoptotic markers **(F)**. **(G)** Experimental scheme of tumor xenograft model established with the indicated cells, and photograph of representative tumors from the six groups (n = 6 per group). **(H)** Comparison of KYSE410FR-miR-CON-CON, KYSE410FR-miR-29c-CON, and KYSE410FR-miR-29c-FBXO31 tumor xenografts in nude mice for 5-FU chemosensitivity. Bars, SD; \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001.](thnov09p1599g004){#F4}

![**STAT5A regulates miR-29c and is inversely correlated with miR-29c expression in ESCC tissues. (A)** Taqman miRNA assay showing the changes in miR-29c expression upon overexpression and knockdown of STAT5A. **(B)** Diagram illustrating the putative STAT5A binding sites in the promoter of miR-29c by in silico prediction. The enrichment of STAT5A in miR-29c promoter region was determined by ChIP-qPCR. **(C)** Upper panel shows the site-specific mutations introduced in the reporter plasmid containing miR-29c promoter (Upper panel). Lower panel shows the luciferase activity in ESCC cells co-transfected with STAT5A-expressing plasmid and the plasmid expressing wide type or mutated miR-29c promoter. **(D)** Representative images of ESCC with immunohistochemical staining scores of 0-3 for STAT5A. **(E)** Two examples of primary ESCC with high immunohistochemical expression of STAT5A, compared with matched normal epithelium. **(F)** Stacked graph showing the expression of STAT5A in 104 cases primary tumor tissue and 75 cases non-tumor tissues. **(G)** Kaplan-Meier analysis based on the 104 tumor tissues showing that STAT5A expression was negatively associated with survival in patients with ESCC (Log Rank = 7.86, P \< 0.01). **(H)** Inverse expression correlation between miR-29c and STAT5A in clinical ESCC tissues. **(I)** Inverse expression correlation between FBXO31 and STAT5A in clinical ESCC tissues. Bars, SD; \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \<0.001.](thnov09p1599g005){#F5}

![**Systemic delivery of miR-29c oligonucleotide overrides 5-FU chemoresistance of FR cells *in vivo*. (A)** Schematic diagram of the miR-29c oligonucleotide treatment experiment and photograph of tumors excised from the control and treatment groups. **(B)** Tumor growth curves showing the chemosensitizing effect of miR-29c oligonucleotide on KYSE410FR-derived tumor xenografts to 5-FU treatment (n = 6). **(C)** Western blot analyses comparing the expressions of cleaved caspase-3 and caspase-3 in the tumors of the four groups of nude mice. **(D)** Quantification of Ki-67 proliferation index in the tumors. **(E)** Body weight of the nude mice in the treatment and control groups as indicated was monitored**. (F)** No significant differences were detected in the blood chemistry and blood cell counts among the groups; ALT (alanine aminotransferase), AST (aspartate aminotransferase), lymphocytes, neutrophils, HGB (hemoglobin), PLT (platelets), RBC (red blood cells), WBC (white blood cells).](thnov09p1599g006){#F6}

![Schematic illustration of how transcriptional regulation of miR-29c by STAT5A can regulate FBXO31 expression and chemoresistance.](thnov09p1599g007){#F7}

###### 

Correlation between STAT5A expression levels and clinicopathological parameters in 104 cases of esophageal cancer.

  Variable               n    Low STAT5A   High STAT5A   P value
  ---------------------- ---- ------------ ------------- ---------
  **Age ( years)**                                       
  ≤55                    20   11           9             
  \>55                   84   40           44            0.552
  **Gender**                                             
  Female                 28   17           11            
  Male                   76   34           42            0.160
  **T-Stage**                                            
  1/2                    16   9            7             
  3/4                    86   42           44            0.586
  **N-Stage**                                            
  N0                     47   29           18            
  N1                     56   22           34            0.023\*
  **Pathologic stage**                                   
  Stages I & II          76   37           39            
  Stages III & IV        28   14           14            0.905
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